| Not Yet Recruiting | Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Comb NCT07385703 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 3 |
| Recruiting | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma NCT07259317 | Corcept Therapeutics | Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the NCT06794073 | Shanghai Zhongshan Hospital | N/A |
| Recruiting | Prospective Data Collection Initiative on Thoracic Malignancies NCT06996249 | Dutch Society of Physicians for Pulmonology and Tuberculosis | — |
| Recruiting | Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Bl NCT06649474 | University Hospital, Clermont-Ferrand | N/A |
| Completed | EchoTip AcuCore Post-Market Clinical Study NCT06358001 | Cook Research Incorporated | — |
| Not Yet Recruiting | Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unre NCT06241469 | Wu Jun | Phase 2 |
| Recruiting | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer NCT05581121 | Institut Claudius Regaud | Phase 3 |
| Unknown | Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE) NCT06090214 | University Hospital, Montpellier | N/A |
| Recruiting | Anatomical-Clinical Base of Adenocarcinoma Pancreatic NCT06128343 | University Hospital, Toulouse | — |
| Recruiting | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the NCT05922930 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Completed | HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Rus NCT05892926 | AstraZeneca | — |
| Recruiting | YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. NCT06337760 | European Institute of Oncology | — |
| Recruiting | Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cance NCT05065736 | Roberto Vargas | EARLY_Phase 1 |
| Recruiting | Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. NCT06046131 | Centre Hospitalier Universitaire de la Guadeloupe | N/A |
| Recruiting | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cance NCT06121700 | Fudan University | Phase 2 |
| Recruiting | Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Canc NCT05574647 | Imperial College London | N/A |
| Completed | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma NCT05678218 | Erasmus Medical Center | — |
| Withdrawn | Methadone for 'Adenocarcinopathic' Pain Treatment NCT05325164 | Ottawa Hospital Research Institute | Phase 3 |
| Active Not Recruiting | A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenva NCT05273554 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility NCT05511116 | Fondation Hôpital Saint-Joseph | — |
| Unknown | Dissecting the Role of MIcrobioMe in gastroEsophageal Tumor: a multIdisCiplinary Longitudinal Study NCT06405035 | European Institute of Oncology | — |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 | Blueprint Medicines Corporation | Phase 1 |
| Completed | A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China NCT05337163 | Creative Biosciences (Guangzhou) Co., Ltd. | — |
| Unknown | Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer NCT04667403 | Institut Cancerologie de l'Ouest | N/A |
| Terminated | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer NCT05161572 | Fudan University | Phase 2 |
| Terminated | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 | Blueprint Medicines Corporation | Phase 1 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929 | Carisma Therapeutics Inc | Phase 1 |
| Recruiting | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcin NCT04069273 | Harry H Yoon | Phase 2 |
| Active Not Recruiting | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Pros NCT04644770 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study NCT04401059 | Tian Xie | Phase 4 |
| Recruiting | Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma NCT04543071 | Gulam Manji | Phase 2 |
| Completed | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CAB NCT04400474 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Terminated | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972 | Hoffmann-La Roche | Phase 3 |
| Completed | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment NCT04263090 | Icahn School of Medicine at Mount Sinai | Phase 1 / Phase 2 |
| Recruiting | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies NCT04361708 | University of Chicago | Phase 1 |
| Recruiting | SERum-bank for PANcreatic Cancer NCT04374175 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Withdrawn | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease NCT01125449 | Situs Cancer Research Center | Phase 2 |
| Unknown | Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer NCT04227886 | Fudan University | — |
| Terminated | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: NCT03997448 | Nataliya Uboha | Phase 2 |
| Terminated | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/ NCT03840967 | Shadia Jalal, MD | Phase 2 |
| Completed | A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) NCT02905578 | Joseph J. Cullen | Phase 2 |
| Unknown | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC NCT03636685 | Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Unknown | A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas NCT03591666 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 |
| Active Not Recruiting | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma NCT03488667 | University of Kansas Medical Center | Phase 2 |
| Completed | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cance NCT03535727 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Completed | A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. NCT03695835 | Gary Onik MD | — |
| Completed | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPL NCT03415854 | HonorHealth Research Institute | Phase 2 |
| Recruiting | PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherap NCT02973828 | Institute of Cancer Research, United Kingdom | — |
| Completed | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Adv NCT02795988 | Imugene Limited | Phase 1 / Phase 2 |
| Completed | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma NCT03000179 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Next Generation Sequencing of Tumor Cells in Locally Advanced Pancreatic Adenocarcinoma NCT03578939 | Istituto Clinico Humanitas | — |
| Withdrawn | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of NCT02943603 | Weijing Sun, MD, FACP | Phase 2 |
| Completed | Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung NCT02410603 | Mayo Clinic | — |
| Completed | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and A NCT03013010 | Shanghai Cancer Hospital, China | Phase 3 |
| Unknown | cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China NCT02980536 | Berry Genomics Co., Ltd. | — |
| Completed | A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT02875340 | ValiSeek Limited | Phase 2 |
| Completed | CTC Pancreatic Adenocarcinoma NCT02335151 | University of Zurich | Phase 4 |
| Completed | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors NCT02926768 | Checkpoint Therapeutics, Inc. | Phase 1 |
| Unknown | Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation NCT02795650 | Hospital Universitario de Fuenlabrada | Phase 2 |
| Completed | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer NCT02428270 | University Health Network, Toronto | Phase 2 |
| Withdrawn | HS-PCI in Locally Advanced Adenocarcinoma of the Lung NCT02341170 | Universitätsmedizin Mannheim | N/A |
| Unknown | LRP1 and Colon Cancer NCT02788669 | CHU de Reims | — |
| Unknown | Metformin Plus Irinotecan for Refractory Colorectal Cancer NCT01930864 | Barretos Cancer Hospital | Phase 2 |
| Completed | Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung NCT02498860 | Chonnam National University Hospital | Phase 2 |
| Terminated | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer NCT02404506 | Swiss Cancer Institute | Phase 2 |
| Terminated | PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma NCT02487277 | Andrew Ko | Phase 2 |
| Terminated | Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer NCT02473094 | University of Campinas, Brazil | Phase 2 |
| Completed | The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomi NCT02394652 | University Health Network, Toronto | Phase 2 |
| Active Not Recruiting | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer NCT02664935 | University of Birmingham | Phase 2 |
| Completed | Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases NCT02426879 | UMC Utrecht | N/A |
| Terminated | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC NCT02387216 | Elevation Oncology | Phase 2 |
| Completed | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of B NCT02213289 | University of Chicago | Phase 2 |
| Unknown | Minimally Invasive Sweet Esophagectomy for Patients With Siewert Type II Adenocarcinoma of the Esophagogastric NCT02741778 | Anhui Provincial Hospital | N/A |
| Completed | Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer NCT02347618 | University of Rochester | N/A |
| Recruiting | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Beyond TME Origins NCT02292641 | Imperial College London | N/A |
| Completed | Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients NCT02374411 | Edward Hospital | — |
| Unknown | Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma NCT02125240 | Betta Pharmaceuticals Co., Ltd. | Phase 3 |
| Completed | A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System NCT02370303 | Mayo Clinic | — |
| Unknown | Cancer-related Thromboembolic Disease NCT02785757 | Hospices Civils de Lyon | N/A |
| Unknown | Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanc NCT02194556 | Betta Pharmaceuticals Co., Ltd. | Phase 4 |
| Completed | Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Eld NCT02151149 | Celgene | Phase 4 |
| Unknown | Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer NCT01952951 | National Cancer Center, Korea | Phase 2 |
| Completed | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer NCT02183870 | University of Cologne | Phase 2 |
| Completed | Dose-Guided Radiotherapy in Oesophageal Cancer: Managing the Real Dose NCT02130011 | Maastricht Radiation Oncology | N/A |
| Unknown | Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Aden NCT02103257 | Betta Pharmaceuticals Co., Ltd. | Phase 4 |
| Completed | HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry NCT02082886 | Edward-Elmhurst Health System | — |
| Terminated | Treatment of Multifocal Lung Adenocarcinoma NCT01946100 | Mayo Clinic | N/A |
| Completed | Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients NCT02454647 | Clinica Universidad de Navarra, Universidad de Navarra | — |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanc NCT01962532 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancrea NCT01761240 | Morphotek | Phase 1 |
| Unknown | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous In NCT01995942 | Royal Marsden NHS Foundation Trust | — |
| Completed | Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies NCT01677559 | Washington University School of Medicine | Phase 1 |
| Terminated | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tum NCT01784861 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Unknown | Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma NCT01665417 | Betta Pharmaceuticals Co., Ltd. | Phase 4 |
| Withdrawn | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases NCT01640847 | Imunon | Phase 2 |
| Unknown | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate He NCT01556815 | Shandong Cancer Hospital and Institute | Phase 2 |
| Completed | Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC1 NCT01778920 | University of Pennsylvania | Phase 1 |
| Completed | Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer NCT01433172 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma NCT01824966 | University Hospital, Gasthuisberg | — |
| Unknown | Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smo NCT01502202 | National Cancer Center, Korea | Phase 2 |
| Completed | Cancer Vaccine Targeting Brachyury Protein in Tumors NCT01519817 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Can NCT01646697 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer NCT01441128 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Prospective Randomized Study of SILS Versus CLS for Rectal Cancer NCT01579721 | Hvidovre University Hospital | Phase 4 |
| Completed | FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma NCT01383538 | Andrew Ko | Phase 1 |
| Completed | Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix NCT01365156 | M.D. Anderson Cancer Center | Phase 3 |
| Terminated | Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy NCT01365143 | Mayo Clinic | Phase 4 |
| Completed | Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) NCT01393483 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resec NCT01295086 | Odense University Hospital | N/A |
| Terminated | Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in Patients With Gastric NCT01476553 | Universitätsmedizin Mannheim | N/A |
| Withdrawn | Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of NCT01301612 | Eurofarma Laboratorios S.A. | Phase 2 |
| Completed | Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas NCT01253525 | Eli Lilly and Company | Phase 1 |
| Unknown | AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreati NCT01182246 | Axcentua Pharmaceuticals AB | Phase 1 / Phase 2 |
| Active Not Recruiting | Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients NCT01171300 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Completed | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer NCT01206530 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Withdrawn | School Response to Families Who Have Children With Cancer NCT01148082 | Stanford University | — |
| Completed | SBRT for Organ Confined Prostate Cancer NCT02653248 | Northwell Health | Phase 1 |
| Completed | Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma NCT01161186 | University of California, San Francisco | Phase 1 |
| Completed | BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) NCT01121393 | Boehringer Ingelheim | Phase 3 |
| Completed | Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE NCT00895349 | Ontario Clinical Oncology Group (OCOG) | N/A |
| Completed | Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or NCT01077817 | Organon and Co | — |
| Completed | CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia NCT01032044 | Mauna Kea Technologies | N/A |
| Terminated | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) NCT01009593 | Abbott | Phase 3 |
| Completed | Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology NCT03462524 | St. James's Hospital, Ireland | — |
| Completed | Chemoradiation and Panitumumab for Esophageal Cancer NCT01077999 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
| Completed | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable NCT01051934 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer NCT00892242 | Washington University School of Medicine | Phase 1 |
| Completed | Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI NCT01020630 | PD Dr Markus Möhler | Phase 2 |
| Unknown | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks NCT01037049 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation NCT00949650 | Boehringer Ingelheim | Phase 3 |
| Completed | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcin NCT00917384 | Eli Lilly and Company | Phase 3 |
| Completed | RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe NCT00688753 | Novartis Pharmaceuticals | Phase 2 |
| Enrolling By Invitation | Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies NCT00923026 | National Cancer Institute (NCI) | — |
| Unknown | Randomized Trial on Robotic Assisted Resection for Rectal Cancer NCT01130233 | The University of Hong Kong | Phase 3 |
| Active Not Recruiting | Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate NCT00911118 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer NCT00940069 | Hunan Province Tumor Hospital | Phase 2 |
| Completed | A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer NCT01249352 | Eurofarma Laboratorios S.A. | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Tr NCT00719264 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy NCT00795184 | Mauna Kea Technologies | N/A |
| Withdrawn | Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric J NCT00800969 | University of Zurich | Phase 2 |
| Completed | Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection f NCT00918853 | Institut Paoli-Calmettes | N/A |
| Completed | Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO) NCT00661830 | PD Dr Markus Möhler | Phase 2 |
| Terminated | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer NCT00672009 | Cedars-Sinai Medical Center | Phase 2 |
| Completed | A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Pat NCT00600821 | Pfizer | Phase 2 |
| Terminated | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung NCT00632203 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of NCT00751543 | National Taiwan University Hospital | N/A |
| Completed | A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With A NCT00548548 | Genentech, Inc. | Phase 3 |
| Unknown | Low Rectal Cancer Study (MERCURY II) NCT02005965 | Royal Marsden NHS Foundation Trust | — |
| Completed | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer NCT00436657 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma NCT00430261 | Swedish Medical Center | Phase 2 |
| Completed | Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenoc NCT00495924 | KU Leuven | — |
| Completed | Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer NCT00395252 | Carmen Schade-Brittinger | Phase 2 |
| Terminated | Identification of Key Blood Molecular Markers for Immunotherapy NCT00507702 | Stanford University | — |
| Completed | Symptom Assessment With Patient Surveys NCT01135823 | Stanford University | — |
| Completed | Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC NCT00321048 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Terminated | Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer NCT00368329 | Stanford University | Phase 1 |
| Completed | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas NCT00443196 | Pierian Biosciences | Phase 2 / Phase 3 |
| Completed | Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus NCT00259987 | GlaxoSmithKline | Phase 2 |
| Completed | Effect of Vitamin D and Calcium on Genes in the Colon NCT00298545 | Rockefeller University | Phase 1 |
| Completed | EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the NCT00377936 | MediGene | Phase 2 |
| Completed | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer NCT00129844 | Pharmacyclics LLC. | Phase 2 |
| Completed | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination NCT00507091 | Genzyme, a Sanofi Company | Phase 1 |
| Terminated | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown P NCT00201734 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors NCT00106353 | Pfizer | Phase 1 / Phase 2 |
| Enrolling By Invitation | Use of Tracking Devices to Locate Abnormalities During Invasive Procedures NCT00102544 | National Institutes of Health Clinical Center (CC) | N/A |
| Completed | ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer NCT00102700 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 |
| Completed | Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma NCT00191503 | Eli Lilly and Company | Phase 2 |
| Completed | Trial of Curcumin in Advanced Pancreatic Cancer NCT00094445 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung NCT00137839 | Pasi A. Janne, MD, PhD | Phase 2 |
| Completed | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer NCT00088413 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospecti NCT00247936 | University of California, Irvine | N/A |
| Completed | Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer NCT00054873 | Chiron Corporation | Phase 2 |
| Terminated | Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) NCT00127036 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Evaluation of Stereotactic Radiosurgery For Liver Malignancies NCT00230347 | Stanford University | Phase 1 |
| Completed | Study of MDX-010 in Stage IV Breast Cancer NCT00083278 | Bristol-Myers Squibb | Phase 2 |
| Terminated | Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer NCT01363466 | UNICANCER | Phase 3 |
| Completed | Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas NCT00051675 | XOMA (US) LLC | Phase 1 |
| Unknown | Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon NCT00201331 | National Health Research Institutes, Taiwan | Phase 2 |
| Completed | Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma NCT00201838 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | A Long Term Safety Study With Atrasentan NCT00127478 | Abbott | Phase 2 / Phase 3 |
| Completed | Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast C NCT00140075 | Pfizer | Phase 3 |
| Completed | Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinom NCT02204046 | Boehringer Ingelheim | Phase 1 |
| Completed | Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan NCT00183859 | University of Southern California | Phase 1 |
| Terminated | Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas NCT00116389 | Point Therapeutics | Phase 2 |